BioCentury
ARTICLE | Clinical News

VML 251 5HTIB/1D agonist data

December 8, 2008 8:00 AM UTC

Full results of a Phase IIb trial of VML 251 in 1000 patients show long half-life with a low rate of headache recurrence. As reported at the Congress of the International Headache Society in Amsterdam, the serotonin mimic was well tolerated and effective in a range of doses from 2.5-40 mg. Response rate was 40-48 percent compared to 22 percent with placebo at two hours.

After four hours, response rates were 64 percent four hours after all doses of drug and 86 percent six hours after the drug compared to 38 percent four hours after placebo and 49 percent six hours after placebo. ...